Prevention of exacerbations of copd with pharmacotherapy

European Respiratory Review

Volumn 19, Issue 116, 2010, Pages 119-126

  Miravitlles, M ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Antibiotics; Bronchodilators; Chronic obstructive pulmonary disease; Exacerbations; Infection; Prevention

Indexed keywords

ACETYLCYSTEINE; AMBROXOL; ANTIBIOTIC AGENT; BACTERIUM LYSATE; BRONCHODILATING AGENT; BUDESONIDE; CARBOCISTEINE; CORTICOSTEROID; ERYTHROMYCIN; FLUTICASONE; FORMOTEROL; IMMUNOFERON; IMMUNOMODULATING AGENT; INFLUENZA VACCINE; INMUNOFERON; LONG ACTING DRUG; MACROLIDE; MOXIFLOXACIN; MUCOLYTIC AGENT; PLACEBO; PNEUMOCOCCUS VACCINE; SALMETEROL; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG;

BACTERIAL COLONIZATION; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE COURSE; DISEASE EXACERBATION; DRUG DOSE COMPARISON; DRUG EFFICACY; HOSPITAL ADMISSION; HUMAN; LUNG FUNCTION; OSTEOPOROSIS; PHYSICAL ACTIVITY; PNEUMONIA; QUALITY OF LIFE; REVIEW; SELF CARE;

ANTI-BACTERIAL AGENTS; BRONCHODILATOR AGENTS; DISEASE PROGRESSION; EXPECTORANTS; HUMANS; IMMUNOLOGIC FACTORS; PNEUMONIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 77953219786     PISSN: 09059180     EISSN: None     Source Type: Journal    
DOI: 10.1183/09059180.00002810     Document Type: Review

References (79)

1. Celli BR, MacNee W, Agusti E, et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-946.
2. Jemal A, Ward E, Hao Y, et al. Trends in the leading causes of death in the United States, 1970-2002. JAMA 2005; 294: 1255-1259.
3. Miravitlles M, Soriano JB, García-Río F, et al. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities. Thorax 2009; 64: 863-868.
4. De Marco R, Accordini S, Cerveri I, et al. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. Thorax 2004; 59: 120-125.
5. Seemungal TAR, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418-1422.
6. Miravitlles M, Ferrer M, Pont A, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. A 2 year follow-up study. Thorax 2004; 59: 387-395.
7. Burrows B, Bloom JW, Traver GA, et al. The course and prognosis of different forms of chronic airways obstruction in a sample from the general population. N Engl J Med 1987; 317: 1309-1314.
8. Burge PS, Calverley PMA, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-1303.
9. Miravitlles M, Murio C, Tirado-Conde G, et al. Geographic differences in clinical characteristics and management of COPD: the EPOCA study. Int J Chron Obstruc Pulmon Dis 2008; 3: 803-814.
10. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008; 31: 416-468.
11. Langsetmo L, Platt RW, Ernst P, et al. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. Am J Respir Crit Care Med 2008; 177: 396-401.
12. Donaldson G, Seemungal T, Patel I, et al. Longitudinal changes in the nature, severity and frequency of COPD exacerbations. Eur Respir J 2003; 22: 931-936.
13. Donaldson GC, Seemungal TAR, Bhomik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847-852.
14. Miravitlles M, Anzueto A, Legnani D, et al. Patient's perception of exacerbations of COPD: the PERCEIVE study. Respir Med 2007; 101: 453-460.
15. Kessler R, Stahl E, Vogelmeier C, et al. Patient understanding, detection, and experience of COPD exacerbations. An observational, interview-based study. Chest 2006; 130: 133-142.
16. Miravitlles M, Calle M, Alvarez-Gutierrez F, et al. Exacerbations, hospital admissions and impaired health status in chronic obstructive pulmonary disease. Qual Life Res 2006; 15: 471-480.
17. Llor C, Molina J, Naberan K, et al. Exacerbations worsen the quality of life of chronic obstructive pulmonary disease patients in primary healthcare. Int J Clin Pract 2008; 62: 585-592.
18. Chodosh S, Schreurs A, Siami G, et al. The efficacy of oral ciprofloxacin vs clarithromycin for the treatment of acute bacterial exacerbations of chronic bronchitis. Clin Infect Dis 1998; 27: 730-738.
19. Wilson R, Allegra L, Huchon G, et al. Short and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004; 125: 953-964.
20. Chodosh S. Clinical significance of the infection-free interval in the management of acute bacterial exacerbations of chronic bronchitis. Chest 2005; 127: 2231-226.
21. Miravitlles M. Exacerbations of chronic obstructive pulmonary disease: when are bacteria important? Eur Respir J 2002; 20: Suppl. 36, 9s-19s.
22. Wilson R, Kubin R, Ballin I, et al. Five day moxifloxacin therapy compared with 7 day clarithromycin therapy for the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1999; 44: 501-513.
23. Sethi S, Evans N, Grant BJ, et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347: 465-471.
24. Sethi S, Sethi R, Eschberger K, et al. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176: 356-361.
25. Black P, Staykova T, Chacko E, et al. Prophylactic antibiotic therapy for chronic bronchitis. Cochrane Database Syst Rev 2003; 1: CD004105.
26. Suzuki T, Yanai M, Yamaya M, et al. Erythromycin and common cold in COPD. Chest 2001; 120: 730-733.
27. Banerjee D, Khair OA, Honeybourne D. The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD. Respir Med 2005; 99: 208-215.
28. Seemungal TAR, Wilkinson TMA, Hurst JR, et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008; 178: 1139-1147.
29. White AJ, Gompertz S, Bayley DL, et al. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax 2003; 58: 680-685.
30. Rosell A, Monso E, Soler N, et al. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch Intern Med 2005; 165: 891-897.
31. Miravitlles M, Marín A, Monsó E, et al. Efficacy of moxifloxacin in the treatment of bronchial colonisation in COPD. Eur Respir J 2009; 34: 1066-1071.
32. Sethi S, Jones PW, Theron MS, et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res 2010; 11: 10.
33. Friedman M, Serby CW, Menjoge SS, et al. Pharmacoeocnomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999; 115: 635-641.
34. Rennard SI, Anderson W, ZuWallack R, et al. Use of long-acting inhaled beta2-adrenergic agonist, salmeterol xinofoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 1087-1092.
35. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinofoate in the treatment of COPD. Chest 1999; 115: 957-965.
36. Aalbers R, Ayres J, Backer V, et al. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-months trial. Eur Respir J 2002; 19: 936-943.
37. Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: 912-919.
38. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 74-81.
39. Puhan MA, Bachmann LM, Kleijnen J, et al. Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis. BMC Med 2009; 7: 2.
40. Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789.
41. Calverley P, Pawels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a rendomised controlled trial. Lancet 2003; 361: 449-456.
42. Gross NJ. Tiotropium bromide. Hot Topics Respir Med 2007; 5: 15-19.
43. Anzueto A, Miravitlles M. Efficacy of tiotropium in the prevention of exacerbations of COPD. Ther Adv Respir Dis 2009; 3: 103-111.
44. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a oncedaily inhaled anticholinergics bronchodilator. Ann Internal Med 2005; 143: 317-326.
45. Dusser D, Bravo M-L, Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J 2006; 27: 547-555.
46. Barr RG, Bourbeau J, Camargo CA, et al. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 2006; 61: 854-862.
47. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-1554.
48. Powrie DJ, Wilkinson TMA, Donaldson GC, et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations of COPD. Eur Respir J 2007; 30: 472-478.
49. Washko GR, Fan VS, Ramsey SD, et al. The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008; 177: 164-169.
50. Jeffery PK. Structural and inflammatory changes in COPD: a comparison with asthma. Thorax 1998; 53: 129-136.
51. Pauwels RA, Lofdahl C-G, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999; 340: 1948-1953.
52. Alsaeedi A, Sin DD, McAlister FA. The effect of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002; 113: 59-65.
53. Jones PW, Willits LR, Burge PS, et al. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003; 21: 68-73.
54. Jenkins CR, Jones PW, Calverley PM, et al. Efficacy of salmeterol/ fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res 2009; 10: 59.
55. De Miguel Díez J, Calle Rubio M, Rodríguez Hermosa JL, et al. Guidelines for the treatment of COPD. Hot Topics Respir Med 2007; 5: 7-14.
56. Roland NJ, Bhalla RK, Earis J. The local side effects of inhaled corticosteroids. Chest 2004; 126: 213-219.
57. Singh S, Amin AV, Loke YK. Long-term use of inhaled corticosteroids and the risk of pneumonia in chronic obstructive pulmonary disease. A meta-analysis. Arch Intern Med 2009; 169: 219-229.
58. Ernst P, Gonzalez AV, Brassard P, et al. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007; 176: 162-166.
59. Hubbard RB, Smith CJP, Smeeth L, et al. Inhaled corticosteroids and hip fracture. A population-based case-control study. Am J Respir Crit Care Med 2002; 166: 1563-1566.
60. Kardos P, Wencker M, Glaab T, et al. Impact of salmeterol/ fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 144-149.
61. Bleecker ER, Emmett A, Crater G, et al. Lung function and symptom improvement with fluticasone propionate/salmeterol and ipratropium bromide/albuterol in COPD: response by beta-agonist reversibility. Pulm Pharmacol Ther 2008; 21: 682-688.
62. Wedzicha JA, Calverley PMA, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008; 177: 19-26.
63. Ferguson GT, Anzueto A, Fei R, et al. Effect of fluticasone propionate/salmeterol (250/50 mcg) or salmeterol (50 mcg) on COPD exacerbations. Respir Med 2008; 102: 1099-1108.
64. Miravitlles M, Anzueto A. Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT studies. Int J Chron Obstruc Pulmon Dis 2009; 4: 185-201.
65. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease. Ann Intern Med 2007; 146: 545-555.
66. Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of the addition of budesonide/formoterol to tiotropium in COPD patients. Am J Respir Crit Care Med 2009; 180: 741-750.
67. Poole PJ, Black PN. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: a systematic review. BMJ 2001; 322: 1271-1274.
68. Decramer M, Rutten-van Molken M, Dekhuijzen PNR, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomised on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005; 365: 1552-1560.
69. Zheng JP, Kang J, Huang SG, et al. Effect of carbocysteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE study): a randomised placebo-controlled study. Lancet 2008; 371: 2013-2018.
70. Steurer-Stey C, Bachmann LM, Steurer J, et al. Oral purified bacterial extracts in chronic bronchitis and COPD. Chest 2004; 126: 1645-1655.
71. Prieto A, Reyes E, Bernstein ED, et al. Defective natural killer and phagocytic activities in chronic obstructive pulmonary disease are restored by glycophosphopeptical (Inmunoferon). Am J Respir Crit Care Med 2001; 163: 1578-1583.
72. Alvarez-Mon M, Miravitlles M, Morera J, et al. Treatment with the immunomodulator AM3 (Inmunoferon) improves the healthrelated quality of life of patients with chronic obstructive pulmonary disease. Chest 2005; 127: 1212-1218.
73. Miravitlles M, Murio C, Morera J, et al. Efecto de AM3 en la calidad de vida de pacientes con enfermedad pulmonar obstructiva crónica en subgrupos de riesgo. [Effect of AM3 on health-related quality of life in patients with chronic obstructive pulmonary disease belonging to risk groups]. Med Clin (Barc) 2008; 130: 688-692.
74. Poole PJ, Chacko E, Wood-Baker RWB, et al. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; 1: CD002733.
75. Alfageme I, Vazquez R, Reyes N, et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 2006; 61: 189-195.
76. Stockley RA, Chopra N, Rice L. Addition of salmeterol to existing treatment in patients with COPD: a 12 month study. Thorax 2006; 61: 122-128.
77. Garcia-Aymerich J, Lange P, Benet M, et al. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax 2006; 61: 772-778.
78. Bourbeau J, Julien M, Maltais F, et al. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease. A disease-specific self-management intervention. Arch Intern Med 2003; 163: 585-591.
79. Wedzicha JA, Seemungal TAR. COPD exacerbations: defining their cause and prevention. Lancet 2007; 370: 786-796.